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Yang-An Wen1, Xiaopeng Xiong1, Yekaterina Y. Zaytseva1,2, Dana L. Napier1, Emma Vallee1, Austin T. Li3, Chi Wang1,
Heidi L. Weiss1, B. Mark Evers1,4 and Tianyan Gao1,5

Abstract
Sterol regulatory element-binding proteins (SREBPs) belong to a family of transcription factors that regulate the
expression of genes required for the synthesis of fatty acids and cholesterol. Three SREBP isoforms, SREBP1a, SREBP1c,
and SREBP2, have been identiﬁed in mammalian cells. SREBP1a and SREBP1c are derived from a single gene through
the use of alternative transcription start sites. Here we investigated the role of SREBP-mediated lipogenesis in
regulating tumor growth and initiation in colon cancer. Knockdown of either SREBP1 or SREBP2 decreased levels of
fatty acids as a result of decreased expression of SREBP target genes required for lipid biosynthesis in colon cancer
cells. Bioenergetic analysis revealed that silencing SREBP1 or SREBP2 expression reduced the mitochondrial respiration,
glycolysis, as well as fatty acid oxidation indicating an alteration in cellular metabolism. Consequently, the rate of cell
proliferation and the ability of cancer cells to form tumor spheroids in suspension culture were signiﬁcantly decreased.
Similar results were obtained in colon cancer cells in which the proteolytic activation of SREBP was blocked.
Importantly, knockdown of either SREBP1 or SREBP2 inhibited xenograft tumor growth in vivo and decreased the
expression of genes associated with cancer stem cells. Taken together, our ﬁndings establish the molecular basis of
SREBP-dependent metabolic regulation and provide a rationale for targeting lipid biosynthesis as a promising
approach in colon cancer treatment.

Introduction
Although diverse in type and underlying genetic
alterations, cancers are fundamentally a disorder of cell
growth and proliferation, which requires increased cellular building blocks, such as nucleic acids, proteins, and
lipids1. To cope with these elevated requirements cancer
cells undergo major metabolic modiﬁcations2,3. There has
been increasing interest in cancer cell metabolism as a
means to understand the functional distinction between
transformed and normal cells and to provide critical
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mechanistic insights regarding cancer development and
progression4. Among metabolic alterations, increased de
novo lipid biosynthesis has been recognized as one of the
important but not well-characterized hallmarks of cancer
cells5. Relatively few studies have rigorously examined the
role of lipogenesis in promoting colorectal cancer (CRC)
and how lipogenic pathways are regulated.
Sterol regulatory element-binding proteins (SREBPs) is
a small family of membrane-bound, basic helix-loop-helix
leucine zipper (bHLH-LZ) transcription factors that regulate the expression of genes required for the synthesis of
fatty acids, triglycerides and cholesterol6–8. Three SREBP
isoforms, SREBP1a, SREBP1c, and SREBP2, have been
identiﬁed in mammalian cells that control distinct but
overlapping lipogenic transcriptional programs7–9. A rich
body of research has demonstrated that SREBP1a
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activates fatty acid and cholesterol synthesis, SREBP1c
fatty acid synthesis, and SREBP2 cholesterol synthesis in
insulin-responsive tissues such as liver and adipose tissue.
The activation process of SREBPs is known to be tightly
controlled by the availability of sterols8,10. Speciﬁcally, the
newly synthesized SREBPs are expressed as inactive precursors and reside as integral trans-membrane proteins
within the endoplasmic reticulum (ER) membrane where
they bind to the sterol-sensing SREBP cleavage-activating
protein (SCAP). When intracellular sterol concentrations
are low, the SREBP/SCAP complex trafﬁcks to the Golgi
where SREBP is cleaved by site-1 and site-2 proteases and
the N-terminal bHLH-LZ domain of the protein is
released and translocated to the nucleus where it binds to
sterol regulatory element (SRE)-sequences in the promoters of its target genes, ultimately increases sterol
levels8–11. As a feedback mechanism to regulate sterol
synthesis, cholesterol and its hydroxylated derivatives,
such as 25-hydroxycholesterol (25-HC), inhibit the proteolytic cleavage and prevent the activation of SREBPs12.
Speciﬁcally, 25-HC binds to ER anchor protein Insig to
promote the formation of SCAP–Insig complex and prevent trafﬁcking of SREBP–SCAP complex to the Golgi13.
Moreover, fatostatin, a non-sterol-like small molecule
inhibitor of SREBP, has been developed to attenuate
SREBP-dependent lipogenesis by binding to SCAP to
block the ER–Golgi translocation of SREBPs14.
In addition to their role in maintaining the homeostasis
of lipid metabolism8, emerging evidence suggests that
increased activation of SREBPs is required to sustain
cancer cell proliferation. For example, activation of
SREBP1 and enhanced expression of its target genes have
been observed in human glioblastoma multiforme carrying activating EGFR mutations and inhibition of lipid
synthesis blocks the growth of xenograft tumors derived
from glioblastoma cells expressing mutant EGFR15. In
addition, it has been shown that the expression of SREBP1
is elevated in prostate cancer patients16. High SREBP1
expression is positively associated with tumor metastasis
and predicts poor prognosis in breast cancer patients17.
Moreover, activation of SREBP as a result of mTORC1
activation downstream of oncogenic PI3K and KRAS
signaling has been shown to promote breast cancer cell
growth and proliferation18. Consistently, the expression of
SREBP target genes, such as fatty acid synthase (FASN)
and steroyl-CoA desaturase (SCD), are also increased in a
variety of human cancers1,19–21. However, the function of
SREBPs in human CRC remains to be fully elucidated.
In this study, we investigated the functional importance
of SREBP-mediated lipogenesis in regulating cellular
metabolism and tumor growth in colon cancer. Inhibiting
lipid biosynthesis by silencing SREBP1, SREBP2 or their
regulator SCAP reduced the rate of cell proliferation as
well as tumor-initiating potential in vitro. Moreover,
Ofﬁcial journal of the Cell Death Differentiation Association
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downregulation of SREBP expression or inhibition of
SREBP activation markedly altered cellular metabolic
pathways. Importantly, knockdown of SREBPs inhibited
xenograft tumor growth and initiation in vivo. Taken
together, our ﬁndings demonstrate that SREBPs have an
important role in promoting tumorigenesis in colon
cancer.

Results
Knockdown of SREBP1 or SREBP2 decreases cell
proliferation and spheroid formation in colon cancer cells

To begin to elucidate the role of SREBP-mediated lipid
biosynthesis in colon cancer, we generated multiple
SREBP1 and SREBP2 knockdown cell lines using two
different lentivirus encoded shRNAs (Fig. 1a, b). Notably,
both SREBP1-speciﬁc shRNAs target common regions in
the SREBP1 gene shared by SREBP1a and SREBP1c isoforms. Downregulation of both the precursor and mature
forms of SREBP1 and SREBP2 protein was conﬁrmed by
western blot analysis in corresponding knockdown cell
lines (Fig. 1c, d). Consistent with their transcription factor
function, silencing SREBPs led to a signiﬁcant decrease in
the expression of target genes in DLD1 and patientderived Pt130 colon cancer cells (Fig. 1e, f). The target
genes of SREBPs tested here are known to involved in
cholesterol uptake and biosynthesis (including LDR
receptor (LDLR), HMG-CoA reductase (HMGCR), and
HMG-CoA synthase (HMGCS)) as well as fatty acid
synthesis (including fatty acid synthase (FASN), acetylCoA carboxylase (ACACA), and stearoyl CoA desaturase
(SCD)). Similar effects on decreasing target gene expression were observed in HCT116 cells (Supplementary
Figure S1). As a consequence, intracellular levels of free
fatty acids (FFA), cholesterol and triglycerides (TAG)
were signiﬁcantly decreased in SREBP knockdown cells
(Fig. 1g).
To investigate the functional effect of silencing SREBPs,
we monitored the rate of cell proliferation in control and
SREBP1 or SREBP2 knockdown DLD1 and Pt130 cells.
Silencing either SREBP1 or SREBP2 was sufﬁcient to
reduce cell growth in both cell lines when compared to
control cells (Fig. 2a, b). Similar results were obtained in
SREBP1 and SREBP2 knockdown HCT116 cells (Supplementary Figure S2a). Furthermore, we determined if
SREBP-dependent lipogenesis is required for maintaining
the tumor initiation potential of colon cancer cells. To
this end, single cells of control and SREBP1 or SREBP2
knockdown DLD1 and Pt130 cells were cultured in suspension stem cell medium, a condition known to enrich
tumor-initiating cells22, and numbers of spheroids (colonies) formed were counted after 6 days. While approximately 10% of control DLD1 and Pt130 cells formed
tumor spheroids in suspension, the numbers of spheroids
were signiﬁcantly decreased in SREBP1 and SREBP2
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(see ﬁgure on previous page)
Fig. 1 Knockdown of SREBP1 or SREBP2 inhibits lipogenesis in colon cancer cells. a, b The real-time PCR analysis of SREBP1 and SREBP2
expression in control and knockdown DLD1 (a) and Pt130 (b) cells. Two different shRNA targeting sequences were used for knocking down SREBP1
or SREBP2. c, d The expression of SREBP1 and SREBP2 proteins were downregulated in stable DLD1 (c) and Pt130 (d) knockdown cells. Protein lysates
from control and knockdown cells were analyzed by western blot. Both the precursor and mature forms of SREBP1 and SREBP2 proteins were
detected. e, f Knockdown of SREBP1 and SREBP2 decreased the expression of downstream genes related to fatty acid synthesis and metabolism in
DLD1 (e) and Pt130 (f) cells. Data represent the mean ± SD (*p < 0.001 and #p < 0.05 compared to sh-Control). g Knockdown of SREBP1 or SREBP2
decreased lipogenesis in colon cancer cells. Total cellular lipids were extracted from control and SREBP knockdown DLD1 and Pt130 cells and the
levels of free fatty acids, cholesterol, and triglyceride were measured and normalized to the amount of total proteins. Data represent the mean ± SD
(*p < 0.001, §p < 0.01, and #p < 0.05 compared to sh-Control)

knockdown cells suggesting inhibition of colony formation
(Fig. 2c, d). In addition, knockdown of SREBP1 and
SREBP2 resulted in a signiﬁcant decrease in the number of
tumor spheroids formed in HCT116 cells (Supplementary
Figure S2b). Consistently, qPCR analysis revealed that the
expression of genes associated with colon cancer stem cells,
including CD44, CD133, LGR5, and AXIN2, was reduced in
SREBP1 and SREBP2 knockdown DLD1 and Pt130 cells
(Fig. 2e). Taken together, these data suggest that SREBP1mediated and SREBP2-mediated lipid biosynthesis has an
important role in supporting cell proliferation and tumor
initiation potential of colon cancer cells.
Inhibition of proteolytic processing of SREBPs decreases
cell proliferation and spheroid formation in colon cancer
cells

We next determined whether inhibition of SREBP activation by blocking proteolytic cleavage has similar effects
as silencing SREBP directly. Consistent with previous
reports, treating cells with 25-HC or fatostatin markedly
decreased the levels of mature (transcriptionally active)
form of SREBP1 and SREBP2 in DLD1 cells as shown by
western blot analysis (Fig. 3a). Similar as those observed in
SREBP1 and SREBP2 knockdown cells, 25-HC-induced
and fatostatin-induced inhibition of SREBPs activation
signiﬁcantly reduced the expression of downstream target
genes important for lipid biogenesis (Fig. 3b). To determine
the functional effect of SREBP inhibition, DLD1 cells were
cultured in the presence of 25-HC or fatostatin. We found
that both fatostatin and 25-HC signiﬁcantly inhibited cell
growth, however, fatostatin showed a strong inhibitory
effect (Fig. 3c). This is likely due to the fact that fatostatin
binds and inhibits SCAP-mediated activation of SREBP in a
sterol-independent manner, whereas 25-HC competes
directly with sterols in cell culture media14. Furthermore,
results from spheroid formation experiments showed that
fatostatin treatment reduced the number of tumor spheroids formed in suspension (Fig. 3d). Interestingly, the 25HC treatment was unable to inhibit tumor spheroid formation (data not shown). As the suspension medium used
in this assay contains high levels of bovine serum albumin
(BSA), BSA-bound lipids may attenuate the 25-HCmediated inhibitory effect. In addition, 25-HC-induced
Ofﬁcial journal of the Cell Death Differentiation Association

and fatostatin-induced inhibition of SREBP activation
decreased expression of genes associated with cancer stem
cells (Fig. 3e).
To further conﬁrm the functional importance of de novo
lipid biosynthesis in colon cancer, we silenced the expression of SCAP, a sterol-sensing SCAP, in DLD1 and Pt130
cells using lentivirus-mediated RNAi. Consistent with its
role in facilitating ER–Golgi translocation and proteolytic
cleavage of SREBPs, downregulation of SCAP resulted in a
similar decrease in the expression of genes required for lipid
biosynthesis (Supplemental Figure S3a). In addition,
knockdown of SCAP inhibited cell proliferation in both
colon cancer cell lines (Supplemental Figure S3b). Furthermore, silencing SCAP signiﬁcantly inhibited tumor
spheroid formation and decreased expression of genes
associated with cancer stem cells (Supplemental Figure S3c,
d). Collectively, these results indicate that inhibition of lipid
biosynthesis, via downregulation of SREBPs or inhibition of
proteolytic cleavage of SREBPs, signiﬁcantly inhibited cell
growth and reduced cancer stem cell properties.
Downregulation of SREBP alters cellular metabolism

Accumulating evidence suggests that alterations in lipid
metabolism contribute to overall metabolic reprogramming in cancer cells1,5,23. To better understand the
mechanism underlying SREBP-mediated regulation of cell
proliferation and stem cell properties, we determined the
functional effect of SREBP-loss on modulating other
metabolic pathways in colon cancer cells. To this end, we
performed Mito Stress Tests using Seahorse XF96
Extracellular Flux Analyzer. Results showed that oxygen
consumption rates (OCR) associated with both basal and
maximal mitochondrial respiration was signiﬁcantly
decreased in SREBP1 and SREBP2 knockdown cells
(Fig. 4a, b). In addition, mitochondrial respiration used for
ATP production and reserved mitochondrial capacities
were reduced in SREBP knockdown cells (Fig. 4a, b).
Moreover, control, SREBP1 and SREBP2 knockdown cells
were subjected to seahorse glycolysis stress tests to evaluate the glycolysis phenotype. Interestingly, silencing
SREBP1 or SREBP2 signiﬁcantly decreased the extracellular acidiﬁcation rate (ECAR) associated with glycolysis, glycolytic capacity and glycolytic reserves in Pt130
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Fig. 2 Knockdown of SREBP1 or SREBP2 inhibits cell proliferation and tumor spheroid formation in colon cancer cells. a, b Knockdown of
SREBP1 or SREBP2 decreased the rate of proliferation in DLD1 (a) and Pt130 (b) cells. Equal number of control and SREBP knockdown cells were
allowed to grow for 4 days and the number of cells were counted each day. Data represent the mean ± SD (§p < 0.01 and #p < 0.05 compared to shControl). c, d Knockdown of SREBP1 or SRBEP-2 decreased the formation of tumor spheroids in the stem cell suspension medium. Control and SREBP
knockdown DLD1 (c) and Pt130 (d) cells were seeded as single cells in the stem cell suspension medium and the number of colonies formed was
determined after 6 days. Data represent the mean ± SD (¶p < 0.0001 and *p < 0.001 compared to sh-Control). e Knockdown of SREBP1 or SRBEP2
reduced the expression of genes associated with colon cancer stem cells. The relative expression of CD44, CD133, LGR5, and AXIN2 mRNA was
determined using real-time PCR in control and SREBP knockdown DLD1 and Pt130 cells. Data represent the mean ± SD (§p < 0.01 and #p < 0.05
compared to sh-Control)

cells (Fig. 4c, d). Similar results were obtained in SREBP1
and SREBP2 knockdown DLD1 cells (data not shown).
Furthermore, bioenergetic measurements of relative utilization of mitochondrial respiration and glycolysis under
basal conditions conﬁrmed that knockdown of either
SREBP reduced both the glycolytic potential and the
mitochondria-mediated oxidative phosphorylation in
colon cancer cells (Fig. 4e). These results suggest that
Ofﬁcial journal of the Cell Death Differentiation Association

SREBP-dependent lipid biogenesis has an important
role in maintaining overall metabolic activity in cancer
cells.
To conﬁrm the effects of SRBEP downregulation on
modulating cellular metabolism, we assessed the levels of
mitochondrial respiration and glycolysis in cells treated
with fatostatin or 25-HC. Bioenergetic measurements
obtained using the Seahorse XF Analyzer showed that
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Fig. 3 Inhibition of SREBP activation decreases cell survival and tumor spheroid formation in colon cancer cells. a Treating cells with 25-HC
(10 μg/ml) or fatostatin (30 μM) blocks the proteolytic processing of SREBPs in DLD1 cells. Protein lysates from control and treated cells were analyzed
for the expression of SREPBs by western blot. b Inhibition of SREBPs decreased the cell survival. DLD1 cells were grown in the presence or absence of
fatostatin and 25-HC for 72 h and numbers of cells was counted. The relative cell growth was calculated by normalizing the number of cells to the
control condition. Data represent the mean ± SD (*p < 0.0001 and #p < 0.05 compared to control untreated cells). c Inhibition of SREBPs decreased
the expression of downstream genes related to fatty acid synthesis and metabolism in DLD1 cells. Data represent the mean ± SD (*p < 0.001, §p <
0.01, and #p < 0.05 compared to control untreated cells). d Fatostatin treatment inhibited the formation of tumor spheroids in the stem cell
suspension medium. DLD1 cells were seeded as single cells in the stem cell suspension medium in the presence of absence of fatostatin and the
number of colonies formed was determined after 6 days. Data represent the mean ± SD (§p < 0.01 compared to untreated cells). e Inhibition of
SREBPs reduced the expression of genes associated with colon cancer stem cells. The relative expression of CD44, CD133, LGR5, and AXIN2 mRNA was
determined using real-time PCR in control and fatostatin or 25-HC treated DLD1 cells. Data represent the mean ± SD (§p < 0.01 and #p < 0.05
compared to control untreated cells)

inhibition of SREBP activation by treating cells with
fatostatin or 25-HC decreased both basal and maximal
mitochondrial respiration as well as mitochondrial
respiration associated with ATP production and reserved
capacities in DLD1 cells (Fig. 5a). In addition, fatostatin or
25-HC treatment signiﬁcantly reduced levels of glycolysis,
glycolytic capacity, and glycolytic reserve (Fig. 5b). The
cell bioenergetic phenotype analysis revealed that inhibition of lipid biogenesis resulted in a decrease in both
mitochondrial oxidative phosphorylation and glycolysis
(Fig. 5c). Similar results were obtained in SCAP knockdown Pt130 cells (Fig. 5e, f). Furthermore, we determined
Ofﬁcial journal of the Cell Death Differentiation Association

whether SREBP expression is associated with cellular
metabolic pathways by analyzing the Cancer Genome
Atlas (TCGA) CRC gene expression data. Indeed, results
from gene set enrichment analysis (GSEA) revealed that
both SREBP1 (gene name: SREBF1) and SREBP2 (gene
name: SREBF2) expression was positively associated with
not only lipid biosynthesis pathways but also glucose
metabolism and TCA cycle in CRC patients (Supplemental Figure S4). Taken together, our results indicate
that the lipid biogenesis pathway is functionally connected
with glycolysis and mitochondrial-dependent metabolic
pathways in CRC.
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Fig. 4 Knockdown of SREBP1 or SREBP2 deregulates glycolysis and mitochondrial respiration in colon cancer cells. a Representative OCR
measurements obtained from the Mito tress test performed in control (sh-Control) and SREBP knockdown (sh-SREBP1 and sh-SREBP2) Pt130 cells
using the Seahorse XF96 Extracellular Flux analyzer. Oligomycin, FCCP, and antimycin A (Anti-A) were added at the indicated points. The shaded areas
indicate the OCR levels associated with basal and maximal respiration, ATP turnover and reserved capacity, respectively. b Experiments as shown in a
were quantiﬁed and the relative levels of OCR associated with basal and maximal respiration, ATP turnover and reserved capacity were calculated.
Data represent the mean ± SEM (¶p < 0.0001 and #p < 0.05 compared to Sh-Control). c Representative ECAR measurements obtained from the
glycolysis stress test performed in control and SREBP knockdown Pt130 cells using the Seahorse XF96 Extracellular Flux analyzer. Glucose, oligomycin,
and 2-deoxyglucose (2-DG) were added at the indicated points. The shaded areas indicate the ECAR levels associated with glycolysis, glycolytic
capacity, and glycolytic reserve, respectively. d Experiments as shown in c were quantiﬁed and ECAR associated with glycolysis, glycolytic capacity,
and glycolytic reserve was calculated. Data represent the mean ± SEM (¶p < 0.0001 compared to Sh-Control). e Knockdown of SREBP resulted in
metabolic shifts in Pt130 cells. The energetic map of control and SREBP knockdown Pt130 cells was based on the measurements obtained in a and c.
The OCR and ECAR data shown in the map represent the OCR of basal respiration from the Mito stress test and the glycolysis-related ECAR from the
glycolysis stress test, respectively (data represent the mean ± SEM)

Downregulation of lipid biogenesis decreases fatty acid
oxidation

In normal insulin-responsive tissues, decreased fatty
acid synthesis is often coupled with increased fatty acid
oxidation (FAO). Here, we determined the effect of
Ofﬁcial journal of the Cell Death Differentiation Association

knocking down SREBPs on FAO in colon cancer cells.
The FAO assays were performed to measure the OCR
levels in the presence or absence of etomoxir (ETO), a
carnitine palmitoyltransferase-1 (CPT-1) inhibitor, using
Seahorse XF Analyzer. As no exogenous fatty acids were
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Fig. 5 Inhibition of SREBP proteolytic processing alters cellular metabolism in colon cancer cells. Control and fatostatin or 25-HC treated
DLD1 cells were subjected to metabolic analysis using the Seahorse XF96 Extracellular Flux analyzer as described in Fig. 4. a The relative levels of OCR
associated with basal and maximal respiration, ATP turnover and reserved capacity were calculated based on the measurements obtained in the Mito
stress test. Data represent the mean ± SEM (¶p < 0.0001 and §p < 0.01 compared to control untreated cells). b The levels of ECAR associated with
glycolysis, glycolytic capacity, and glycolytic reserve were calculated based on the measurements obtained in the glycolysis stress test. Data represent
the mean ± SEM (¶p < 0.0001 and §p < 0.01 compared to control untreated cells). c The energetic map of control and treated DLD1 cells was based
on the measurements obtained in a and c. The OCR and ECAR data shown in the map represent the OCR of basal respiration from the Mito stress test
and the glycolysis-related ECAR from the glycolysis stress test, respectively (data represent the mean ± SEM). d Control and SCAP knockdown Pt130
cells were subjected to metabolic analysis using the Seahorse XF96 Extracellular Flux analyzer. The relative levels of OCR associated with basal and
maximal respiration, ATP turnover and reserved capacity were calculated based on the measurements obtained in the Mito stress test. Data represent
the mean ± SEM (¶p < 0.0001 compared to Sh-Control). e The levels of ECAR associated with glycolysis, glycolytic capacity and glycolytic reserve was
calculated based on the measurements obtained in the glycolysis stress test. Data represent the mean ± SEM (*p < 0.001 and §p < 0.01 compared to
Sh-Control). f The energetic map of control and SCAP knockdown Pt130 cells was derived from the measurements obtained in d and e. The OCR and
ECAR data shown in the map represent the OCR of basal respiration from the Mito stress test and the glycolysis-related ECAR from the glycolysis
stress test, respectively (data represent the mean ± SEM)

added in the assays, the differences in the OCR measurements were used to determine the utilization of
endogenous fatty acids. Intriguingly, results obtained in
control and SREBP1 and SREBP2 knockdown DLD1 and
Pt130 cells showed that silencing either SREBP signiﬁcantly reduced the levels of FAO in both cell lines
(Fig. 6a, b). Similarly, knockdown of SCAP decreased the
Ofﬁcial journal of the Cell Death Differentiation Association

levels of FAO in both DLD1 and Pt130 cells (Fig. 6c). In
supporting a functional connection between SREBPmediated lipid biosynthesis and FAO in cancer cells,
results from our GSEA study showed that the expression
of SREBP1 and SREBP2 was positively correlated with the
fatty acid metabolism pathway in CRC patient samples
(Supplemental Figure S4). Taken together, these results
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(Fig. 7e, f), Consistent with the results obtained in cultured cells, the expression of genes associated with cancer
stem cells, including CD44, CD133, LGR5, and AXIN2,
was signiﬁcantly decreased in SREBP1 and SREBP2
knockdown tumors (Fig. 7g). Furthermore, to conﬁrm the
effect of SREBP downregulation on reducing the stemness
of colon cancer cells, we performed tumor initiation
experiments by injecting control and SREBP1 and
SREBP2 knockdown Pt130 cells at 1000 cells per site in
NSG mice. The number of tumors formed was determined after 3 months. While control cells were able to
form tumors at 6 out of 8 injection site, the tumor
forming ability of SREBP1 and SREBP2 knockdown cells
was decreased (Fig. 7h), suggesting that silencing SREBPs
inhibits tumor initiation. Collectively, our results
demonstrate that SREBP-dependent lipid biosynthesis
promotes colon cancer tumorigenesis.

Discussion
Fig. 6 Downregulation of SREBP decreases fatty acid oxidation in
colon cancer cells. a, b Knockdown of SREBP1 and SREBP2 reduced
fatty acid oxidation (FAO) in DLD1 (a) and Pt130 (b) cells. The rate of
cellular FAO was determined by subjecting control and SREBP
knockdown cells to the FAO assays using the Seahorse XF96
Extracellular Flux analyzer. Data represent the mean ± SEM (§p < 0.01
compared to Sh-Control). c Knockdown of SCAP reduced FAO in
DLD1 and Pt130 cells. The rate of cellular FAO was determined using
Seahorse FAO assays. Data represent the mean ± SEM (#p < 0.05,
compared to Sh-Control)

suggest that inhibition of SREBP-mediated lipogenesis not
only reduces the need for glycolysis and mitochondrial
respiration but also decreases the rate of FAO in colon
cancer cells.
Silencing SREBP inhibits xenograft tumor growth in vivo

Given that inhibition of lipid biosynthesis by silencing
SREBPs decreases cell proliferation and stemness in colon
cancer cells, we next investigated the functional effects of
SREBP-mediated lipid biosynthesis in controlling tumor
growth in vivo. To this end, control and SREBP1- or
SREBP2 knockdown Pt130 cells were injected subcutaneously into NSG mice and the tumorigenesis process
was monitored over 28 days. We found that silencing
SREBP1 or SREBP2 signiﬁcantly reduced the rate of
tumor growth over the follow-up period and decreased
the average weight of tumors (Fig. 7a, b). In addition,
tumor sections were stained with the Ki67 and cleaved
caspase-3 antibodies to determine the rate of cell proliferation and apoptosis, respectively. IHC staining results
showed that the numbers of Ki67-positive cells were signiﬁcantly decreased in SREBP1 and SREBP2 knockdown
tumors indicating decreased cell proliferation (Fig. 7c, d).
In contrast, the numbers of cleaved caspase-3-positive
cells were increased indicating elevated levels of apoptosis
Ofﬁcial journal of the Cell Death Differentiation Association

Cancer cells are rapidly dividing cells that have
increased demands for energy and macromolecules.
Emerging evidence suggests that the primary functions of
activated oncogenes and inactivated tumor suppressors
are to rewire cellular metabolic pathways in order to drive
tumorigenesis24. Whereas most normal human cells utilize exogenous sources of fatty acids, tumors often exhibit
a shift toward de novo lipid biosynthesis, despite the
availability of extracellular lipids5,25,26. Here we show that
inhibition of lipid biosynthesis by knocking down SREBP1
or SREBP2 signiﬁcantly inhibits cell proliferation in vitro
and tumorigenesis in vivo as a result of decreased fatty
acid and cholesterol levels in colon cancer cells. In addition, silencing SREBP1 or SREBP2 expression in both
established cancer cell lines and patient-derived cancer
cells results in an overall shift in cellular metabolism as
indicated by reduced levels of glycolysis, mitochondrial
respiration as well as FAO. Importantly, knockdown of
SREBPs inhibits the tumor initiation capacity of colon
cancer cells and reduces the expression of cancer stem
cell-associated genes. Furthermore, blocking the proteolytic processing of SREBP by treating cell with inhibitors
or silencing SCAP, results in a similar inhibition of cell
proliferation and alteration of cellular metabolism, thus
conﬁrming the functional importance of SREBPdependent lipid biosynthesis. Taken together, results
from our studies establish a role of SREBPs in promoting
tumor growth and initiation in colon cancer.
Although it has been suggested that SREBP1 controls
fatty acid and cholesterol synthesis whereas SREBP2
preferentially activates cholesterol synthesis9, genes related to fatty acid and cholesterol synthesis are similarly
downregulated in SREBP1 and SREBP2 knockdown
colon cancer cells and the functional outcomes are mostly
comparable upon silencing either isoforms. One

Wen et al. Cell Death and Disease (2018)9:265

Page 10 of 14

Fig. 7 Knockdown of SREBP inhibits xenograft tumor growth and tumor initiation. a Control, SREBP1, and SREBP2 knockdown Pt130 cells were
injected subcutaneously into NSG mice. The size of the tumors was measured every 3 days starting at day 14. Data represent the mean ± SEM (¶p <
0.0001 compared to Sh-Control group). b On day 29, tumors were excised and weighted. Data represent the mean ± SEM (¶p < 0.0001 and §p < 0.01
compared to Sh-Control group). c Detection of proliferating cells in tumors with IHC staining using the anti-Ki67 antibody. Scale bar, 25 μm. d
Numbers of Ki67-positive cells were quantiﬁed in 500 randomly chosen tumor cells. Data in the graph represent the mean ± SD (¶p < 0.0001
compared to Sh-Control group). e Detection of apoptotic cells in tumors with IHC staining using the anti-cleaved caspase-3 antibody. Scale bar, 25
μm. f Numbers of cleaved caspase-3-positive cells were quantiﬁed in 500 randomly chosen tumor cells. Data in the graph represent the mean ± SD
(¶p < 0.0001 compared to Sh-Control group). g Knockdown of SREBP reduced the expression of genes associated with colon cancer stem cells. The
relative expression of CD44, CD133, LGR5, and AXIN2 mRNA was determined using real-time PCR in tumors derived from control, SREBP1 and SREBP2
knockdown Pt130 cells. Data represent the mean ± SD (*p < 0.001, §p < 0.01, and #p < 0.05 compared to Sh-Control group). h Tumor initiation
experiments were performed using control, SREBP1, and SREBP2 knockdown Pt130 cells. The cells were mixed with Matrigel and subcutaneously
inoculated into NSG mice at 1000 cells per site and total of eight injections were used for each cell line. The number of tumors formed was
determined 3 months post inoculation.
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exception is that silencing SREBP1 has a stronger effect
on reducing mitochondrial respiration compared to
SREBP2. It is of particular interest to investigate if
SREBP1 regulates expression of genes that are coupled
directly with mitochondrial functions in future studies.
Previous studies on deﬁning the speciﬁcity of SREBP
isoforms are generally conducted in the context of liver
metabolism by overexpressing SREBP27,28. Our ﬁndings
here suggest that SREBP1 and SREBP2 may have overlapping functions in colon cancer cells.
As a part of metabolic reprogramming, altered lipid
metabolism has been increasingly recognized as an
important hallmark of cancer cells1,2. In normal insulinresponsive tissues, such as liver and adipose tissue,
decreased the cellular FAO can lead to increased production and accumulation of fatty acids29. Intriguingly, we
ﬁnd that inhibition of SREBP-mediated lipid biosynthesis
reduces the mitochondrial activity associated with both
glycolysis and FAO in colon cancer cells. These results
suggest that levels of glucose metabolism are dictated by
the need for lipid production in cancer cells, and fatty
acids derived from de novo lipid biosynthesis are used to
fuel tumor growth. Collectively, our ﬁndings highlight the
signiﬁcance of metabolic ﬂexibility that adapted by cancer
cells to fulﬁll the energy requirement for proliferation and
survival. However, additional studies are needed to elucidate the molecular mechanism that allows the coupling
of lipogenesis with FAO and other metabolic pathways in
cancer cells. Recent studies using genome-wide ChIP-Seq
approach have identiﬁed previously unknown target genes
of SREBP1 and SREBP2 that are beyond lipid biosynthesis
regulation30,31. For example, SREBP2 has been shown to
directly activates autophagy related genes under sterol
starvation condition31. In addition, it has been shown that
inhibition of SREBP activation prevents cytokine-induced
metabolic reprogramming in NK cells32. Thus, lipid
biosynthesis-independent functions of SREBPs may also
contribute to the regulation of cellular metabolism in
colon cancer cells.
Given the notion that elevated lipid biosynthesis promotes tumorigenesis and tumor progression, targeting de
novo lipogenesis represents an attractive option in
developing new therapeutic agents in cancer treatment33.
Indeed, it has been shown that depletion of SREBP1 and
SREBP2 expression induces ER-stress, accumulation of
reactive oxygen species and apoptosis in breast cancer and
glioblastoma cells34. Downregulation of SREBP1 expression inhibits cell growth, migration and invasion and
induces apoptosis in ovarian cancer cells35. Furthermore,
fatostatin suppresses xenograft tumor growth of prostate
and breast cancer cells36,37. In our effort to determine the
levels of SREBP1 and SREBP2 expression in human CRC,
we performed bioinformatics analysis using the
Cancer Genome Atlas (TCGA) gene expression database.
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However, we did not ﬁnd any signiﬁcant increase in
SREBP1 or SREBP2 expression in CRC patient samples
compared to normal controls (data not shown). As the
RAS/RAF and PI3K/AKT pathway are commonly activated in CRC, the activity of SREBPs may be increased via
a post-translational mechanism downstream of Akt/
mTOR rather than at the transcript level11,15,18.
Our study provides initial evidence that SREBPmediated tumor promoting effects may be partially
blocked by fatostatin. However, the overall anti-tumor
effect of SREBP inhibition likely depends on the availability of exogenous lipids and the activation status of
lipogenic signaling in cancer cells18,33,34. It remains an
open question which types of cancer (or which cancer
patients) are most likely to respond to therapies targeting
de novo lipid biosynthesis pathways. Interestingly,
increased lipid droplet formation has been observed in a
subpopulation of colon cancer cells that express CD133, a
putative marker of cancer stem cells, suggesting that
cancer stem cells may maintain a higher level of lipid
biosynthesis38. In addition, recent studies indicate that
leukemia stem cells preferentially rely on FAO for the
maintenance of stem cell properties23,39. We show here
that silencing SREBP reduces FAO and the “stemness” of
colon cancer cells as indicated by decreased colony formation ability in vitro and tumor initiation in vivo.
Therefore, inhibition of lipid biosynthesis may provide an
effective approach for targeting cancer stem cells.
In summary, results from our study demonstrate the
functional importance of SREBP-mediated lipid biosynthesis in colon cancer. Future studies are needed to
further explore the molecular mechanism by which lipogenesis regulates cancer stem cell properties and the
potential application of therapeutic agents targeting lipid
metabolism in cancer.

Materials and methods
Cells and reagents

Human colon cancer cell lines DLD1 and HCT116
cells were cultured in DMEM and McCoy’s 5A supplemented with 10% fetal bovine serum (FBS, SigmaAldrich, MO, USA) and 1% penicillin–streptomycin,
respectively. These cells were purchased from ATCC
and authenticated using short tandem repeat (STR)
DNA proﬁling in March 2016 (Genetica, OH, USA).
Primary colon cancer Pt130 cells were established from
patient-derived xenografts (PDX) as described previously40. Brieﬂy, this cell line, obtained from a 63-year
old male with moderately differentiated colonic adenocarcinoma, contains BRAF (V600E) and TP53 mutations
and was authenticated using short tandem repeat (STR)
DNA proﬁling as a unique cancer cell line (Genetica).
Stable SREBP1, SREBP2 and SCAP knockdown cells
were generated using lentivirus-based RNAi40–42. The
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shRNA targeting sequences for SREBP1 (also named
SREBF1) are as the following: 5′-GCCATCGACTACATTCGCTTT-3′ (a) and 5′-CCAGAAACTCAA
GCAGGAGAA-3′ (b); for SREBP2 (also named
SREBF2): 5′-CCTCAGATCATCAAGACAGAT-3′ (a)
and 5′-GACCTGAAGATCGAGGACTTT-3′ (b); and
for SCAP: 5′-GCTCAACGGTTCCCTTGATTT-3′ (a)
and 5′-GCTCTGGTGTTCTTGGACAAA-3′ (b). The
non-targeting control shRNA lentivirus plasmid (MISSION, SHC002) was obtained from Sigma-Aldrich (MO,
USA). Fatostatin and 25-HC were purchased from
Sigma-Aldrich.
Real-time PCR

Total RNA was isolated from human cancer cells or
xenograft tumors using RNeasy kit (Qiagen, MD, USA).
Equal amounts of RNA were used as templates for the
synthesis of cDNA using High Capacity cDNA Reverse
Transcription kit (Applied Biosysems, CA, USA). Realtime PCR reaction was performed using TaqMan probes
speciﬁc for SREBP1, SREBP2, LDLR, FASN, SCD, ACACA,
HMGCS, HMGCR, LGR5, CD44, CD133, LGR5, and
AXIN2 using StepOne Real-Time PCR system (Applied
Biosysems). All values were normalized to the level of βactin.
Measurements of cellular fatty acid, cholesterol, and
triglyceride levels

Equal numbers of colon cancer cells were seeded in 6well plate in regular growth medium. After 16 h incubation, cells were lysed and extracted according to procedures speciﬁed by individual quantiﬁcation kits. The Free
Fatty Acid Quantiﬁcation Kit, Cholesterol Quantiﬁcation
Kit (Sigma-Aldrich), and Triglyceride Colorimetric Assay
Kit (Cayman, MI, USA) were used to quantify levels of
cellular fatty acids, cholesterol, and triglyceride,
respectively.
Cell proliferation assay

To determine the rate of proliferation, equal numbers of
cells were seeded into 12-well plates (2 × 104 cells per
well). The number of cells were counted daily for 4 days
using a cell counter (Beckman-Coulter, Fullerton, CA,
USA).
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Seahorse extracellular ﬂux analysis

The Seahorse XF96 Extracellular Flux Analyzer (Agilent, CA, USA) was used to measure the respiration
activity of colon cancer cells. Cells were seeded at the
density of 3 × 104 cells per well in a XF96 plate ~16 h
before the measurement. The glycolysis and mitochondrial stress test were performed according to manufacturer’s protocol. All Seahorse measurements were
normalized to the protein contents in each well. The
relative levels of glycolysis, glycolytic capacity, and glycolytic reserve were calculated based on ECAR data
obtained in the glycolysis stress tests, whereas the relative
levels of basal, maximal, ATP production-related
respiration, and reserved mitochondrial capacity
were calculated based on OCR data obtained in the Mito
stress tests using Seahorse Wave software for XF
analyzers.
To measure the rate of cellular FAO, cells were incubated overnight in Substrate-Limited Medium (DMEM
with 0.5 mM glucose, 1.0 mM glutamine, 0.5 mM carnitine, and 1% FBS) in XF96 cell culture plates. Forty-ﬁve
minutes prior to the beginning of OCR measurement, the
cells were switched to the FAO Assay Medium (111 mM
NaCl, 4.7 mM KCl, 2.0 mM MgSO4, 1.2 mM Na2HPO4,
2.5 mM glucose, 0.5 mM carnitine, and 5 mM HEPES).
Etomoxir (40 µM) was added to one set of cells to reveal
the amount of FAO-associated OCR. All Seahorse measurements were normalized to the protein concentrations
in each well. The FAO-dependent respiration was calculated by subtracting OCR levels in ETO-treated cells from
those in untreated cells.
Western blot analysis

Colon cancer cells were harvested and detergentsolubilized cell lysates were obtained as described previously41–44. Equal amounts of cell lysates were resolved
by SDS-PAGE and subjected to western blot analysis. The
SREBP1 antibody was from BD Biosciences (CA, USA),
whereas the SREBP2 antibody was from R&D Systems
(MN, USA). Note that the SREBP antibodies recognize
both the precursor and mature active forms of the
respective proteins. The γ-tubulin antibody was from
Sigma-Aldrich.
Xenograft tumor formation

Spheroid formation assay

To determine the self-renewal capacity of colon cancer
cells, 1,000 single cells were seeded in non-adherent 24well plates in StemPro hESC SFM medium supplied with
1% GlutaMAX, 2% StemPro hESC supplement, 1.8% BSA,
8 ng/ml FGF-basic, and 0.1 mM 2-mercaptoethanol
(Thermo Fisher Scientiﬁc, MA, USA). After 6 days in
culture, numbers of spheroids were counted under a light
microscope.
Ofﬁcial journal of the Cell Death Differentiation Association

All animal procedures were done using protocols
approved by the University of Kentucky Animal Care and
Use Committee. Six to eight week-old NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG, The Jackson Laboratory) mice were
used. Both male and female mice of equal numbers were
included in each group. Control and SREBP knockdown
Pt130 cells were collected in 50% Matrigel in DMEM and
inoculated subcutaneously at 1 × 106 cells per injection
site. After 2 weeks, the tumor size was measured every
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3 days with a caliper, and the tumor volume was deﬁned
as (longest diameter) × (shortest diameter)2/2. At the end
of experiments, tumors were harvested, weighted and
ﬁxed in 10% buffered formalin. The parafﬁn embedded
samples were prepared, and 5 µm sections were used for
IHC staining. For tumor initiation assay, Pt130 cells (1000
cells/injection site) were injected subcutaneously in NSG
mice. The number of tumors formed was determined
3 months post injection.
Immunohistochemical (IHC) staining

Parafﬁn embedded xenograft tumor sections were
deparafﬁnized, rehydrated, and treated with hydrogen
peroxide. Antigen retrieval was performed using Dako
Target Retrieval Solution (Agilent), and IHC staining was
performed as previously described40,42. The anti-Ki67
antibody was from Dako (Agilent, CA, USA) and the
cleaved caspase-3 antibody was from Cell Signaling. The
stained sections were visualized using a Nikon Eclipse 80i
upright microscope. Tumor sections from three different
mice per group were stained and examined. In each
stained section, numbers of Ki67 or cleaved caspase-3positive cells were counted in seven randomly chosen
images and the percentage of staining positive cells were
quantiﬁed by normalizing to total numbers of cells.
Results shown in Fig. 7 represent average results obtained
in three mice.
Statistical analysis

In experiments to assess the rate of cell proliferation,
mRNA expression, fatty acid and triacylglycerol (TAG)
levels, bioenergetic measurements, and tumor weight
were summarized using bar or line graphs and pairwise
comparisons between different conditions were carried
out using two-sample t-tests. A linear mixed model was
employed to compare slope of tumor volume growth
curves over time between groups. The relative mRNA
expression results shown in Figs. 1–3 and 7 represent
average of three separate qPCR experiments with four
replicates for each gene in each experiment. For the
Seahorse experiments, eight replicates were included for
each cell line in each experiment and the experiments
were repeated three times. Results shown in Figs. 4–6
were from one representative experiment. All other
experiments were repeated three times and results shown
represent the average of three experiments.
For the Gene Set Enrichment Analysis (GSEA), RNA
sequencing data were obtained from the TCGA CRC
study. Correlations between expressions of SREBP1 (gene
name: SREBF1) and SREBP2 (gene name: SREBF2) and
the other genes were quantiﬁed by Spearman’s correlation
coefﬁcient. The genes were then ordered from highest to
lowest based on the correlation coefﬁcient. This ranked
list was inputted into the GSEA Desktop Application45 to
Ofﬁcial journal of the Cell Death Differentiation Association
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identify pathways that are associated with SREBP
expression.
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